In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK announced that its drug Jemperli (dostarlimab) has received the US FDA ...

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

24 Jul, 2018 11 Sep, 2018 1:1 For every 1 share held; Holder will receive 1 bonus shares. 28 Sep, 1994 02 Jan, 1995 1:1 For every 1 share held; Holder will receive 1 bonus shares. 23 Jun, 1980-1:3 ...

If each of you 9 million annual website visitors donated just $1 a year, we'd never worry about funding again. Will you help us follow the money?

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This report highlights the key figures of the GlaxoSmithKline in India and its place in the pharmaceutical market in the country. Information on the company's KPIs along with key competitors is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...